Pharvaris N.V. (NASDAQ:PHVS) Receives Average Rating of “Moderate Buy” from Analysts

Pharvaris N.V. (NASDAQ:PHVS) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $40.5556.

PHVS has been the topic of a number of recent analyst reports. Wedbush lifted their price target on Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Guggenheim raised their target price on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Wednesday, December 3rd. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Finally, Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, February 7th.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc lifted its stake in shares of Pharvaris by 27.4% in the 2nd quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock worth $1,751,000 after acquiring an additional 21,388 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the second quarter worth approximately $57,000. Geode Capital Management LLC lifted its position in Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter.

Pharvaris Stock Up 0.4%

PHVS stock opened at $28.10 on Monday. The firm’s 50-day simple moving average is $26.34 and its 200 day simple moving average is $24.50. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $29.80.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.